A recent study also showed that MCM patients with a rare heterozygote variant of LPL appear to have an intermediate risk of developing pancreatitis with an intermediate phenotype between MCM patients without rare variants and FCS patients; potentially enabling identification of higher-risk MCS patients who would benefit from additional treatment14. Here, LPL is linked to pancreatitis.